Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer

Acta Urologica Japonica

Volumn 53, Issue 2, 2007, Pages 99-104

  Numata, Kousaku ^a   Miura, Noriyoshi ^a   Azuma, Koji ^a   Karashima, Takashi ^a   Kasahara, Kotaro ^a   Nakatsuzi, Hironori ^a   Hashine, Katsuyoshi ^a   Sumiyoshi, Yoshiteru ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Estramustine phosphate; Etoposide; Hormone refractory prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRAMUSTINE; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PROSTATE TUMOR; SURVIVAL RATE; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; ETOPOSIDE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 33947426472     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. American Cancer Society: Cancer Facts and Figures 2005. Atlanta, Ga: American Cancer Society, 2005
2. Cancer mortality and morbidity statistics-Japan and the world 2004. Japan Cancer Association
3. Smaletz O, Scher HI, Small EJ, et al.: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972-3982, 2002
4. Jonsson G, Hogberg B and Nilsson T: Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt). Scand J Urol Nephrol 11: 231-238, 1977
5. Benson RC, Wear JB and Gill GM: Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J Urol 121: 452-454, 1979
6. Smith MR, Kaufman D, Oh W, et al.: Vinorelbine and estramustine in androgen-independent metastatic prostate cancer. Cancer 89: 1824-1828, 2000
7. Seidman AD, Scher HI, Petrylak D, et al.: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147: 931-934, 1992
8. Hudes GR, Nathan F, Khater C, et al.: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156-3163, 1997
9. Pienta KJ, Redman B, Hussan M, et al.: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005-2012, 1994
10. Sumiyoshi Y, Hashine K, Nakatsuzi H, et al.: Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. Int J Urol 7: 243-247, 2000
11. rd ed. Japanese Urological Association, Japanese Society of Pathology 2001
12. Stearns ME, Wang M, Tew KD, et al.: Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU. J Cell Biol 107: 2647-2656, 1988
13. Iversen P, Rosmussen F, Amussen C, et al.: Eatramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA Study 9002. J Urol 157: 929-934, 1997
14. Nelson WG, Liu LF and Coffey DS: Newly replicated DNA is associated with DNA topoisomerase II in cultures rat prostatic adenocarcinoma cells. Nature 322: 187-189, 1986
15. Hussen MH, Pienta KJ, Redman BG, et al.: Oral Etoposide in the treatment of hormone-refractory prostate cancer. Cancer 74: 100-103, 1994
16. Pienta KJ and Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 149: 1622-1625, 1993
17. Pienta KJ, Redman BG, Bandekar R, et al.: A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50: 401-407, 1997
18. Dimopoulos MA, Panopoulos C, Bamia C, et al.: Oral estramustine and oral etoposide for hormonerefractory prostate cancer. Urology 50: 754-758, 1997
19. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 35: 1502-1512, 2004
20. Petrylak DP, Tangen CM, Hussain MH, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 35: 1513-1520, 2004
21. Ringle I and Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991